A Trial Investigating the Accuracy and Precision of the BGStar® and iBGStar® Blood Glucose Meter in Subjects With Type 1 Diabetes

Profil Institut für Stoffwechselforschung GmbH1 site in 1 country20 target enrollmentNovember 2012

ConditionsDiabetes Mellitus

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Diabetes Mellitus
Sponsor: Profil Institut für Stoffwechselforschung GmbH
Enrollment: 20
Locations: 1
Primary Endpoint: Mean absolute relative deviation (MARD) from paired reference values of BGStar®, iBGStar® and comparator BG meter measurements at stable hypoglycaemic, euglycaemic and hyperglycaemic levels and overal
Status: Completed
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Due to continuing technological progress and better understanding of the needs for glucose monitoring, the performance requirements of blood glucose meters, primarily regarding their accuracy, are constantly debated and keep evolving as a consequence. Recently a discussion was initiated by the Food and Drug Administration (FDA) to improve the accuracy of BG meters in the point-of-care testing setting by asking for fulfilment of higher requirements.

Registry

clinicaltrials.gov

Start Date

November 2012

End Date

January 2014

Last Updated

12 years ago

Study Type

Interventional

Study Design

Factorial

Sex

All

Investigators

Sponsor

Profil Institut für Stoffwechselforschung GmbH

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Signed and dated informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
•Male or female subjects aged 18-74 years (both inclusive).
•Type 1 diabetes mellitus (as diagnosed clinically) ≥ 12 months.
•Body mass index 18.0-28.0 kg/m2 (both inclusive).
•HbA1c ≤ 9.0 % by local laboratory analysis.

Exclusion Criteria

•Known or suspected hypersensitivity to lancet fingerpricks / needle injections.
•Previous participation in this trial. Participation is defined as having performed at least one BG meter measurement as part of the study.
•Receipt of any investigational medicinal product within 30 days before randomisation in this trial.
•Formation of callus on the fingertips or any other skin condition that may hamper fingerprick blood sampling and/or insufficient capillary blood volume sampling (\< 50 μL) during test fingerprick(s).
•Haemoglobin \< 8.0 mmol/L (male) or \< 6.4 mmol/L (female), total leukocyte count \< 3.0 x 109/L, thrombocytes \<100 x 109/L, serum creatinine levels ≥ 126 μmol/L (male) or ≥ 111 μmol/L (female), bilirubin \> 3x the upper limit of normal (ULN), and alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and gamma-glutamyl transferase (γ-GT) \> 2 x ULN.
•Suffer from or history of a life threatening disease (i.e. cancer except basal cell skin cancer or squamous cell skin cancer), or any clinically significant respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological (with the exception of diabetes mellitus and euthyroid struma), haematological, dermatological, venereal, -

Outcomes

Primary Outcomes

Mean absolute relative deviation (MARD) from paired reference values of BGStar®, iBGStar® and comparator BG meter measurements at stable hypoglycaemic, euglycaemic and hyperglycaemic levels and overal

Time Frame: 6 hours